SRZN NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Surrozen Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 22.21 USD
12.6% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -11.4% below the Trend Line and sits at 50.8% of its 52-week range. The latest completed week returned 12.6%, after a -10.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: earnings are due in 13d.

Setup score 40 out of 100
Latest Close 22.21 USD 31 Jul 2026
1W Return 12.6% latest completed week
4W Return -10.9% short-term follow-through
12W Return -23.3% quarterly tape
Trend Breadth 73.1% 38 of 52 weeks active
Volume Ratio 2.9x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 12.6% Latest completed week; four-week move -10.9%. Indicator stack 40/34 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 53/100 48 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -11.4% below the Trend Line and sits at 50.8% of its 52-week range. The latest completed week returned 12.6%, after a -10.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.9x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2812-week average 0.62

12-week confirmation

Trend active4/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.28Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers11 reversal markers

No recent accumulation markers. 1 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -10.9% over four weeks, -23.3% over 12 weeks, and 101.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W12.6%
4W-10.9%
12W-23.3%
26W3.1%
52W101.9%
Active trend streak0 weeks
Active weeks in one year38
Trend breadth73.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.87Latest activity-pressure read.
Pressure change-3.6%Four-week change in activity pressure.
Leadership-1.10Latest relative-leadership reading.
RS change-110.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength35/100Blend of value, momentum, and quality. Underlying universe rank 66; rank 1 is best.
Value43/100Relative valuation strength. Underlying universe rank 58; rank 1 is best.
Quality42/100Profitability and accounting quality. Underlying universe rank 59; rank 1 is best.
Momentum43/100Medium-term price momentum. Underlying universe rank 58; rank 1 is best.
Growth43/100Revenue and earnings growth. Underlying universe rank 58; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
30.6x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-25.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
99.1%
Gross profit retained from each unit of revenue.
Operating margin
-4571.1%
Operating profit retained from revenue.
Free-cash-flow margin
-443.5%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-35.6%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-36.6%
Net share repurchases relative to market value.
Shareholder yield
-36.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity14 / 6

14 acquisitions and 6 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment53/100

Weighted news tone is neutral across 48 relevant articles.

11 positive · 29 neutral · 8 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-36.5%Distance below the 52-week high.
13-week volatility8.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+19.4%Week of 1 May.
Worst week-17.9%Week of 5 Jun.
Latest week+12.6%Week of 31 Jul.

Shape of recent returns

Strong gains10
Modest gains1
Flat weeks0
Modest losses7
Sharp losses8
Recent vol8.5%13-week weekly-return volatility.
Base vol10.0%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew9.1% / -6.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape44/100

Trend, activity pressure, participation, and risk combine to a 44/100 tape read.

 Indicator analysis37/100

Latest 12-week confirmation: trend 4/12, activity pressure 2/12, relative leadership 9/12.

Activity pressure 0.28; 1 reversal markers Factors39/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 95; Small Cap Core rank 58 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 48 relevant articles.

Surrozen Inc (SRZN) Financial Health: Profitability & Balance Sheet Analysis Insiders14 / 6

14 acquisitions and 6 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 14 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202622.21 USD12.6%25.07 USD13.39 USD-0.87-1.102.3MOff
24 Jul 202619.73 USD-10.2%25.05 USD13.33 USD-0.98-11.01833.6KOff
17 Jul 202621.96 USD-5.3%25.13 USD13.28 USD-0.79-1.781.0MOff
10 Jul 202623.19 USD-6.9%25.12 USD13.22 USD-0.770.40686.5KOff
3 Jul 202624.92 USD-1.2%25.17 USD13.15 USD-0.8410.93541.1KOff
26 Jun 202625.22 USD8.5%25.02 USD13.05 USD-0.9314.621.4MOff
19 Jun 202623.25 USD-0.6%24.73 USD12.94 USD-1.082.12781.2KOff
12 Jun 202623.39 USD8.7%24.40 USD12.85 USD-1.146.30436.9KOff
5 Jun 202621.52 USD-17.9%24.05 USD12.77 USD-0.950.98463.9KOn
29 May 202626.21 USD-0.6%23.74 USD12.69 USD-0.5018.53498.6KOn
22 May 202626.37 USD-6.3%23.33 USD12.58 USD0.1224.23431.4KOn
15 May 202628.15 USD-2.8%22.91 USD12.47 USD0.6136.09335.2KOn
8 May 202628.96 USD-13.8%22.43 USD12.35 USD1.2141.99547.5KOn
1 May 202633.60 USD19.4%21.92 USD12.22 USD1.3476.59491.1KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.